MedPage Today on MSN
Trial Patient Dies After Receiving CRISPR Gene Therapy
A patient with transthyretin amyloidosis (ATTR) who received the investigational gene therapy nexiguran ziclumeran (nex-z) in ...
Fierce Biotech
Patient dies after receiving Intellia's CRISPR therapy
The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...
Clinical Trials Arena on MSN
Intellia Therapeutics’ stock rocked by patient death in gene therapy trial
A patient dosed with Intellia Therapeutics’ CRISPR gene therapy has died after suffering a severe liver-associated adverse ...
GEN - Genetic Engineering and Biotechnology News
Patient Dies After Treatment with Intellia CRISPR Therapy in Phase III Trial
Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with ...
Fierce Pharma
FDA restricts Sarepta's gene therapy Elevidys after Duchenne patient deaths
The updated label now includes a boxed warning and a new “limitation of use" in addition to the removal of the prior ...
FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
The Food and Drug Administration is adding a new warning to a gene therapy linked to two patient deaths earlier this year ...
Becker's Hospital Review
Intellia trial participant dies after severe liver reaction
Intellia Therapeutics temporarily paused dosing and screening for its phase 3 Magnitude and Magnitude-2 trials of Nex-z following a patient hospitalization, according to an Oct. 27 news release. The ...
MedPage Today on MSN
Amid Safety Investigation, ATTR Gene Therapy Buoyed by Good 3-Year Data
In an update on nex-z's phase I study, the CRISPR-Cas9 gene therapy stayed the course out to 3 years in an initial 36-person ...
MedPage Today
Gene Therapy Gets FDA's Strongest Warning After Fatal Liver Injuries
The FDA added a boxed warning to delandistrogene moxeparvovec (Elevidys) gene therapy for Duchenne muscular dystrophy and changed the indication of the drug after reports of fatal liver injury emerged ...
Fierce Biotech
FDA puts Tenaya heart disease gene therapy clinical trial on hold
The FDA has put a clinical hold on a Tenaya Therapeutics gene therapy study | The FDA has put a clinical hold on a Tenaya ...
BioSpace
Patient Dies After Receiving Intellia’s CRISPR Gene Therapy Candidate
The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred. Intellia is working with experts to create a risk management program for nex ...